Navigation Links
Amylin to Advance Key Value-Driving Opportunities in 2011
Date:1/10/2011

ate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates, such as the BYDUREON NDA, or sNDAs for label expansion requests may not be submitted timely or receive FDA approval;  risks that our response to the FDA's BYDUREON complete response letter may not be submitted in a timely manner and/or the information we provide in our response may not satisfy the FDA; risks that the FDA may request additional information prior to approving BYDUREON; risks that we will not be successful in our efforts to advance new forms and delivery options for exenatide; risks that we will not submit the remaining components of the BLA mentioned in this press release in a timely manner; risks that we will not submit the IND or initiate the clinical study mentioned in this press release for AC165198 in a timely manner; risks that our efforts to drive operational efficiencies and preserve cash will not produce the results we expect and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
2. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
3. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
5. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
6. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
7. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & Metabolomics ... cell technology start-up company Asymmetrex to share the first report on progress ... new biomarker for counting adult tissue stem cells. , With a name like “H2A.Z ...
(Date:8/25/2015)... and CARDIFF, UK (PRWEB) , ... August 25, ... ... and accurately determining whether breast tissue lesions are cancerous is described by University ... SPIE, the international society for optics and photonics. , In “ Breast cancer ...
(Date:8/25/2015)... 25, 2015 Human Longevity, Inc. (HLI), the genomics-based, ... has joined the company as Chief Operating Officer. Winham, who ... and technical experience, will report directly to HLI,s CEO, ... new role as COO, Winham will be responsible for managing ... as all facility operations. HLI currently has three locations in ...
Breaking Biology Technology:New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... launched its revolutionary Trusted LASIK Surgeons directory service and ... a resource for consumers seeking to improve their vision. ... a unique screening process ensuring that only those who ... laser eye surgery in the United States are listed. ...
... Dec. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc (NASDAQ: ... Battle Against Cancer, panel at the RBC Capital Markets ... am ET at the Westin Times Square Hotel in ... Chief Executive Officer, Scott Cormack, will provide a brief ...
... Support ConjuChem,s, R&D Efforts ... and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies ... of Novozymes A/S (LSE:NVZ) announced today that the Companies ... by which Novozymes Biopharma will exclusively supply its recombinant ...
Cached Biology Technology:Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 2Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 3Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 4Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 5Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 6Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 7ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... enzymes that taxi electrons to chemicals outside the cell, ... energy flow in the cell and, in turn, keeps ... a little like that slogan for a hyper-electrified desert ... there. , Now, scientists for the first time ...
... Using advanced new microscopy techniques in concert with ... have for the first time created three-dimensional, time-lapse ... live tumor tissues. In recorded experiments, immune cells ... though tissues, making direct contact with tumor cells, ...
... Chemical Senses Center report that bitter taste perception of ... taste genes and the presence of naturally-occurring toxins in ... 19 issue of Current Biology. , Scientists have long ... to detect potentially harmful toxins in plants. The ...
Cached Biology News:Biofuel cells without the bio cells 2Innovative movies show real-time immune-cell activity within tumors 2Innovative movies show real-time immune-cell activity within tumors 3Bitter taste identifies poisons in foods 2
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
8.1.1...
... NAP-10 Columns, 50. For rapid and efficient ... in less than 15 minutes by gravity ... distilled water containing 0.15% Kathon CG/ICP Biocide.Available ... 0.5 ml (NAP-5), 1 ml (NAP-10) ...
Human Serpin A3 MAb (Clone 213907)...
Biology Products: